@bubu12
Emergency Use Authorization (EUA) for an Unapproved
Product
Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization
Review Memorandum
Pfizer-BioNTech COVID-19 Vaccine study results of 44,000
participants ; 2 months after the second shot : 8 “cases” of Covid19 in the
Vaccine group and 162 “cases” in the placebo group. It’s “95% effective".
What is the definition of a case ?
"the case definition for a confirmed COVID-19 case was
the presence of at least one of the following symptoms and a positive
SARS-CoV-2 NAAT within 4 days of the symptomatic period :
• Fever ;
• New or increased cough ;
• New or increased shortness of breath ;
• Chills ;
• New or increased muscle pain ;
• New loss of taste or smell ;
• Sore throat ;
• Diarrhea ;
• Vomiting
• Fatigue ;
• Headache ;
• Nasal congestion or runny nose ;
• Nausea..
NO ONE DIED in both
groups from Covid19 !
The placebo was 100%
effective at preventing death !...
No data was provided
about hospitalizations !
Interestingly, 1
person died 3 days after injection ; but it’s “unclear” if the vaccine killed him
...
Here’s the text from the Emergency Use Authorization
application Pfizer submitted to the FDA :
“efficacy in preventing confirmed COVID-19 occurring at
least 7 days after the second dose of vaccine was 95.0%, with 8 COVID-19 cases
in the vaccine group and 162 COVID-19 cases in the placebo group....Secondary
efficacy analyses suggested benefit of the vaccine in preventing severe
COVID-19 and in preventing COVID-19 following the first dose, although available
data for these outcomes did not allow for firm conclusions".
"A 2-month
median follow-up is the shortest follow-up period to achieve some confidence
that any protection against COVID-19 is likely to be more than short-lived.
“
" However, risk of vaccine-enhanced disease over time,
potentially associated with waning immunity, remains unknown and needs to be
evaluated further in ongoing clinical trials and in observational studies that
could be conducted following authorization and/or licensure ".